How Novartis’s Sandoz Has Performed
Novartis’s (NVS) Sandoz, a market leader in differentiated generics, saw its revenue grow 4% YoY (year-over-year) to ~$2.5 billion in Q1 2018, boosted by 8% due to foreign exchange and offset by a 4% decline in operating revenue. The chart below shows Sandoz’s quarterly revenue since Q1 2017.